melanoma
Showing NaN - NaN of 66
Melanoma Trial in Worldwide (Immunotherapeutic GSK2132231A)
Completed
- Melanoma
- Immunotherapeutic GSK2132231A
-
Los Angeles, California
- +62 more
Dec 7, 2020
Melanoma Trial in Worldwide (pembrolizumab + epacadostat, pembrolizumab + )
Completed
- Melanoma
- pembrolizumab + epacadostat
- pembrolizumab + placebo
-
Birmingham, Alabama
- +128 more
Aug 14, 2020
Melanoma, Metastatic Melanoma Trial in Dallas (SAbR, Ipilimumab, Nivolumab)
Withdrawn
- Melanoma
- Metastatic Melanoma
- SAbR
- +2 more
-
Dallas, TexasUniversity of Texas Southwestern Medical Center - Dallas
Aug 19, 2020
Melanoma Trial in United States (glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1
Terminated
- Melanoma
- glembatumumab vedotin
- +3 more
-
Los Angeles, California
- +13 more
Sep 5, 2019
Urothelial Carcinoma, Melanoma, Cervical Carcinoma in Situ Trial in Dallas (SAbR Treatment of Lesions)
Completed
- Urothelial Carcinoma
- +2 more
- SAbR Treatment of Lesions
-
Dallas, TexasUniversity of Texas Southwestern Medical Center
Jan 8, 2019
Melanoma Trial in Worldwide (Tasisulam-sodium, Paclitaxel)
Terminated
- Melanoma
-
Birmingham, Alabama
- +121 more
Jun 18, 2018
Melanoma Trial in Dallas (Trametinib (2mg)/Digoxin (.25mg))
Completed
- Melanoma
- Trametinib (2mg)/Digoxin (.25mg)
-
Dallas, TexasUT Southwestern Medical Center
May 9, 2018
Melanoma Trial in Dallas (Digoxin Combination, Dabrafenib, Trametinib)
Withdrawn
- Melanoma
- Digoxin Combination
- +2 more
-
Dallas, TexasUniversity of Texas Southwestern Medical Center
May 9, 2018
Melanoma Trial in Dallas (Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90
Terminated
- Melanoma
- Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV
- Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.
-
Dallas, TexasUniversity of Texas Southwestern Medical Center
Dec 28, 2016
Collecting Tumor Samples From Patients With Gynecological Tumors
Completed
- Borderline Ovarian Clear Cell Tumor
- +85 more
- Laboratory Biomarker Analysis
-
Fayetteville, Arkansas
- +186 more
Oct 26, 2016
Melanoma Trial in Worldwide (ipilimumab (MDX-010, BMS-734016))
Completed
- Melanoma
- ipilimumab (MDX-010, BMS-734016)
-
Little Rock, Arkansas
- +53 more
Sep 27, 2016
Melanoma Trial in Worldwide (Talimogene laherparepvec, GM-CSF)
Completed
- Melanoma
- Talimogene laherparepvec
- GM-CSF
-
Tucson, Arizona
- +82 more
Jun 14, 2016
Melanoma, Cancer Trial in Canada, United States (ALVAC(2) Melanoma multi-antigen therapeutic vaccine, Intron A, Interferon alpha
Terminated
- Melanoma
- Cancer
- ALVAC(2) Melanoma multi-antigen therapeutic vaccine
- Intron A, Interferon alpha -2b
-
Tucson, Arizona
- +18 more
Apr 12, 2016
Melanoma Trial in United Kingdom, United States (Talimogene Laherparepvec, Granulocyte Macrophage Colony-Stimulating Factor
Completed
- Melanoma
- Talimogene Laherparepvec
- Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
-
Chicago, Illinois
- +9 more
Nov 12, 2015